Abstract
Most HIV-negative individuals exposed to Mycobacterium tuberculosis (Mtb) control infection as latent TB infection (LTBI), but HIV co-infection greatly increases progression to tuberculosis (TB), the leading cause of death in people living with HIV (PLHIV). Although combination antiretroviral therapy (cART) reduces LTBI reactivation, immune control of Mtb is not fully restored, as shown by persistent TB incidence in PLHIV on cART. In macaques, skewed pulmonary effector memory CD4⁺ T-cell (TEM) responses and new TB lesions persist despite cART. We hypothesize that concurrent anti-TB therapy with cART would improve bacterial control and immune restoration compared to cART alone. Using rhesus macaques (RM) with LTBI and Simian Immunodeficiency Virus (SIV...
Abstract
Most HIV-negative individuals exposed to Mycobacterium tuberculosis (Mtb) control infection as latent TB infection (LTBI), but HIV co-infection greatly increases progression to tuberculosis (TB), the leading cause of death in people living with HIV (PLHIV). Although combination antiretroviral therapy (cART) reduces LTBI reactivation, immune control of Mtb is not fully restored, as shown by persistent TB incidence in PLHIV on cART. In macaques, skewed pulmonary effector memory CD4⁺ T-cell (TEM) responses and new TB lesions persist despite cART. We hypothesize that concurrent anti-TB therapy with cART would improve bacterial control and immune restoration compared to cART alone. Using rhesus macaques (RM) with LTBI and Simian Immunodeficiency Virus (SIV) co-infection, we tested three months of weekly isoniazid and rifapentine (3HP) plus daily cART. Concurrent cART+3HP improves clinical and microbiological outcomes but fails to fully restore lung CD4⁺ T-cell immunity. Treated RMs retain caseous granulomas with high FDG uptake and incomplete CD4⁺ T-cell reconstitution, marked by persistent activation, exhaustion, and inflammation. CD4⁺ TEM cells remain depleted. Concurrent therapy induces Type I IFN signatures and enhances Mtb-specific TH1/TH17—but reduces TNFα—responses. These findings reveal persistent pulmonary immune defects underlying TB risk in HIV co-infection and identify potential targets for host-directed adjunctive therapies.
Data availability
The scRNA-seq data generated in this study have been deposited in the NCBI Gene Expression Omnibus database under accession code GSE293173. The scRNA-seq data generated in this study are provided in the Supplementary Information/Source Data file. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293173. Accession for Bulk RNA-seq SRA data: PRJNA1327945. https://trace.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA1327945%20&o=acc_s%3Aa Source data are provided with this paper.
References
Wong, N. S. et al. A longitudinal study on latent TB infection screening and its association with TB incidence in HIV patients. Sci. Rep. 9, 10093 (2019).
Dravid, A. et al. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India. BMC Infect. Dis. 19, 714 (2019).
Ahmed, A., Mekonnen, D., Shiferaw, A. M., Belayneh, F. & Yenit, M. K. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study. BMJ Open 8, e016961 (2018).
Liu, E. et al. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS 29, 1391–1399 (2015).
Lawn, S. D., Myer, L., Bekker, L. G. & Wood, R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 20, 1605–1612 (2006).
Suthar, A. B. et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 9, e1001270 (2012).
Adhikari, N. et al. Prevalence and associated risk factors for tuberculosis among people living with HIV in Nepal. PLoS One 17, e0262720 (2022).
Danel, C. et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N. Engl. J. Med. 373, 808–822 (2015).
Badje, A. et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob. Health 5, e1080–e1089 (2017).
Rangaka, M. X. et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 384, 682–690 (2014).
Semitala, F. C. et al. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 18, e1003875 (2021).
Chaisson, L. H. et al. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine. AIDS 37, 1097–1101 (2023).
Sharan, R. et al. Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs. J. Clin. Invest. 132, e161564 (2022). 1.
Bucsan, A. N. et al. Mechanisms of reactivation of latent tuberculosis infection due to SIV co-infection. J. Clin. Invest. 129, 5254–5260 (2019). 1.
Sharan, R. et al. Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model. J. Clin. Invest. 132, e153090 (2022). 1.
Kuroda, M. J. et al. High turnover of tissue macrophages contributes to tuberculosis reactivation in simian immunodeficiency virus-infected Rhesus Macaques. J. Infect. Dis. 217, 1865–1874 (2018).
Foreman, T. W. et al. CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection. Proc. Natl. Acad. Sci. USA 113, E5636–E5644 (2016).
Sharan, R. et al. Chronic immune activation in TB/HIV co-infection. Trends Microbiol. 28, 619–632 (2020).
Ganatra, S. R. et al. Anti-retroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV co-infection model. J. Clin. Invest. 130, 5171–5179 (2020). 1.
Ganatra, S. R. et al. Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model. J. Clin. Invest. 130, 5171–5179 (2020).
Sharan, R. et al. Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a tuberculosis/simian immunodeficiency virus coinfection model. J. Clin. Invest. 132, e153090 (2021). 1.
Singh, B. et al. Inhibition of indoleamine dioxygenase leads to better control of tuberculosis adjunctive to chemotherapy. JCI Insight. 8, e163101 (2023). 1.
Singh, B. et al. Indoleamine-2,3-dioxygenase inhibition improves immunity and is safe for concurrent use with cART during Mtb/SIV coinfection. JCI Insight. 9, e179317 (2024). 1.
Shanmugasundaram, U. et al. Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment. JCI Insight. 5, e137858 (2020). 1.
Arlehamn, C. L. et al. Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features. J. Immunol. 193, 2931–2940 (2014).
Gosselin, A. et al. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J. Immunol. 184, 1604–1616 (2010).
Dawson, R. et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS ONE 4, e6984 (2009).
Schwander, S. & Dheda, K. Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am. J. Respir. Crit. Care Med. 183, 696–707 (2011).
Mehra, S. et al. Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus. J. Med. Primatol. 40, 233–243 (2011).
Sharan, R., Singh, D. K., Rengarajan, J. & Kaushal, D. Characterizing early T cell responses in nonhuman primate model of tuberculosis. Front. Immunol. 12, 706723 (2021).
Singh, D. K. et al. Prevention of tuberculosis in cynomolgus macaques by an attenuated Mycobacterium tuberculosis vaccine candidate. Nat. Commun. 16, 1957 (2025).
Li, G. et al. Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8+ T effector levels in Han Chinese pulmonary TB patients. Microbes Infect. 22, 119–126 (2020).
Cavalcanti, Y. V., Brelaz, M. C., Neves, J. K., Ferraz, J. C. & Pereira, V. R. Role of TNF-alpha, IFN-gamma, and IL-10 in the development of pulmonary tuberculosis. Pulm. Med. 2012, 745483 (2012).
Allie, N. et al. Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci. Rep. 3, 1809 (2013).
Olsen, A. et al. Targeting Mycobacterium tuberculosis tumor necrosis factor alpha-downregulating genes for the development of antituberculous vaccines. mBio 7, e01023-15 (2016). 1.
Mehta, A. K., Gracias, D. T. & Croft, M. TNF activity and T cells. Cytokine 101, 14–18 (2018).
Pollock, K. M. et al. T-cell immunophenotyping distinguishes active from latent tuberculosis. J. Infect. Dis. 208, 952–968 (2013).
Harari, A. et al. Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat. Med. 17, 372–376 (2011).
Ogongo, P. et al. High-parameter phenotypic characterization reveals a subset of human Th17 cells that preferentially produce IL17 against M. tuberculosis antigen. Front. Immunol. 15, 1378040 (2024). 1.
Moreira-Teixeira, L., Mayer-Barber, K., Sher, A. & O’Garra, A. Type I interferons in tuberculosis: Foe and occasionally friend. J. Exp. Med. 215, 1273–1285 (2018).
Kotov, D. I. et al. Early cellular mechanisms of type I interferon-driven susceptibility to tuberculosis. Cell 186, 5536–5553 e5522 (2023).
Esaulova, E. et al. The immune landscape in tuberculosis reveals populations linked to disease and latency. Cell Host Microbe 29, 165-178.e168 (2020). 1.
Scott, N. R. et al. S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis. J. Clin. Invest. 130, 3098–3112 (2020).
Berry, M. P. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973–977 (2010).
Ahmed, M. et al. Immune correlates of tuberculosis disease and risk translate across species. Sci. Transl. Med. 12, eaay0233 (2020). 1.
Akter, S. et al. Mycobacterium tuberculosis infection drives a type I IFN signature in lung lymphocytes. Cell Rep. 39, 110983 (2022).
Chowdhury, C. S. et al. Type I IFN-mediated NET release promotes Mycobacterium tuberculosis replication and is associated with granuloma caseation. Cell Host Microbe 32, 2092–2111 e2097 (2024).
Dooley, K. E. et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV 7, e401–e409 (2020).
Kaushal, D., Mehra, S., Didier, P. J. & Lackner, A. A. The non-human primate model of tuberculosis. J. Med Primatol. 41, 191–201 (2012).
Scanga, C. A. & Flynn, J. L. Modeling tuberculosis in nonhuman primates. Cold Spring Harb. Perspect. Med 4, a018564 (2014).
Flynn, J. L., Gideon, H. P., Mattila, J. T. & Lin, P. L. Immunology studies in non-human primate models of tuberculosis. Immunol. Rev. 264, 60–73 (2015).
Gideon, H. P. et al. Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control. Immunity 55, 827–846.e810 (2022).
Mpande, C. A. M. et al. Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection. EBioMedicine 64, 103233 (2021).
Counoupas, C. & Triccas, J. A. The generation of T-cell memory to protect against tuberculosis. Immunol. Cell Biol. 97, 656–663 (2019).
Gehad, A. et al. A primary role for human central memory cells in tissue immunosurveillance. Blood Adv. 2, 292–298 (2018).
Robert, M. & Miossec, P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cell Mol. Immunol. 18, 1644–1651 (2021).
Mundra, A. et al. Pathogenicity of type I interferons in Mycobacterium tuberculosis. Int. J. Mol. Sci. 24, 3919 (2023). 1.
McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87–103 (2015).
Mayer-Barber, K. D. & Yan, B. Clash of the cytokine titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell Mol. Immunol. 14, 22–35 (2017).
Moreira-Teixeira, L. et al. Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis. Nat. Commun. 11, 5566 (2020).
Xu, G., Wang, J., Gao, G. F. & Liu, C. H. Insights into battles between Mycobacterium tuberculosis and macrophages. Protein Cell 5, 728–736 (2014).
Apelbaum, A., Yarden, G., Warszawski, S., Harari, D. & Schreiber, G. Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol. Cell Biol. 33, 800–814 (2013).
Prezzemolo, T. et al. Functional signatures of human CD4 and CD8 T cell responses to mycobacterium tuberculosis. Front Immunol. 5, 180 (2014).
Lawn, S. D., Gupta, A. & Wood, R. Assessing the impact of prevalent tuberculosis on mortality among antiretroviral treatment initiators: accurate tuberculosis diagnosis is essential. AIDS 26, 1730–1731 (2012).
Gupta, A., Wood, R., Kaplan, R., Bekker, L. G. & Lawn, S. D. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PloS ONE 7, e34156 (2012).
Manca, C. et al. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J. Immunol. 162, 6740–6746 (1999).
Dijkman, K. et al. Disparate tuberculosis disease development in macaque species is associated with innate immunity. Front. Immunol. 10, 2479 (2019).
Barreiro, L. B., Marioni, J. C., Blekhman, R., Stephens, M. & Gilad, Y. Functional comparison of innate immune signaling pathways in primates. PLoS Genet. 6, e1001249 (2010).
Bucşan, A. N. et al. Mechanisms of reactivation of latent tuberculosis infection due to SIV coinfection. J. Clin. Invest. 129, 5254–5260 (2019).
Mehra, S. et al. The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. J. Infect. Dis. 205, 1203–1213 (2012).
Mehra, S. et al. Granuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis. J. Infect. Dis. 207, 1115–1127 (2013).
Kaushal, D. et al. Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis. Nat. Commun. 6, 8533 (2015).
Singh, D. K. et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat. Microbiol. 6, 73–86 (2021).
Stammes, M. A. et al. Recommendations for standardizing thorax PET-CT in non-human primates by recent experience from macaque studies. Animals 11, 204 (2021). 1.
Mattila, J. T. et al. Positron emission tomography imaging of macaques with tuberculosis identifies temporal changes in granuloma glucose metabolism and integrin α4β1-expressing immune cells. J. Immunol. 199, 806–815 (2017).
Sakai, S. et al. Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates. Mucosal Immunol. 14, 1055–1066 (2021).
Li, Q., Skinner, P. J., Duan, L. & Haase, A. T. A technique to simultaneously visualize virus-specific CD8+ T cells and virus-infected cells in situ. J. Vis. Exp. 1561 (2009).
Acknowledgements
This work was supported by National Institutes of Health investigator- AI111943 (awarded to D.K.), AI123047 (to D.K.), OD031898 (to D.K.), AI170148 (to D.K.), R21AI170148 (to R.S.), K01OD031898 (to R.S.), institutional- grants OD010442, AI168439, AI161943, OD028732, OD032443 and CPRIT Core Facility Award (RP220662). We also acknowledge the role of institutional grants U42OD10442 (to D.K.), P30AI168439 (Texas D-CFAR, co-director D.K., and P30AI161943 (IN-TRAC; both R.S. and D.K. are members). SIVmac239 was graciously provided by Drs. Preston Marx and Nick Manness, Tulane National Primate Research Center. SIV viral load assays were performed by the NHP Core Virology Laboratory for AIDS Research and Development, Division of AIDS, NIAID. PMPA and FTC were provided by Gilead Sciences, and DTG was provided by Viiv Healthcare. Data was generated in the Genome Sequencing Facility, which is supported by UT Health San Antonio, NIH Shared Instrument grant S10OD030311 (S10 grant to NovaSeq 6000 System), S10OD028732 (to SNPRC).
Author information
Author notes
Bindu Singh
Present address: Department of Biological Sciences, Indian Institute of Science Education and Research, Bhopal, MP, India
Authors and Affiliations
Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
Riti Sharan, Bindu Singh, Vinay Shivanna, Edward J. Dick Jr., Shannan Hall-Ursone, Xavier Alvarez, Smriti Mehra & Deepak Kaushal 1.
Greehey Children’s Cancer Research Institute, Long School of Medicine, UT Health, San Antonio, TX, USA
Yi Zou 1.
UTHealth Houston School of Public Health, Houston, TX, USA
Xi Luo, Guanlin Guo & Hulin Wu 1.
Bernard and Betty Roizman Professor and Chair, University of Chicago Department of Microbiology and Immunology, Chicago, IL, USA
Shabaana A. Khader 1.
Emory Vaccine Center and Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA, USA
Jyothi Rengarajan 1.
Greehey Children’s Cancer Research Institute, Department of Molecular Medicine, Long School of Medicine, UT Health, San Antonio, TX, USA
Zhao Lai
Authors
- Riti Sharan
- Yi Zou
- Bindu Singh
- Vinay Shivanna
- Edward J. Dick Jr.
- Shannan Hall-Ursone
- Xi Luo
- Guanlin Guo
- Shabaana A. Khader
- Xavier Alvarez
- Jyothi Rengarajan
- Zhao Lai
- Smriti Mehra
- Hulin Wu
- Deepak Kaushal
Contributions
R.S., J.R., and D.K. designed the study. R.S. and B.S. performed sample collection and processing. V.S. and E.J. performed macaque necropsies and pathology studies. S.H.U. was the attending veterinarian for the study. X.A. performed the PET/CT and related analysis. R.S., Z.L., Y.Z., X.L., G.G., H.W., and D.K. performed the data analysis. Z.L. performed quality control of BAL cells, 10x scRNA-seq and NGS workflow. S.A.K., J.R., and S.M. helped R.S. and D.K. in writing the manuscript.
Corresponding authors
Correspondence to Riti Sharan or Deepak Kaushal.
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Sharan, R., Zou, Y., Singh, B. et al. Concurrent TB and HIV therapies control TB reactivation during co-infection but not chronic immune activation. Nat Commun (2025). https://doi.org/10.1038/s41467-025-67188-4
Received: 16 August 2024
Accepted: 24 November 2025
Published: 12 December 2025
DOI: https://doi.org/10.1038/s41467-025-67188-4